2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow MCL: new trials by email Literature Review of MCL trials Research Report on MCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Tafasitamab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 4 | 2023-03-14 | 2025-05-25 |
| Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas 90Y-DOTATOC - DLBCL, MCL | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 | 2016-12-22 | 2018-03-19 |
Lymphoma, Mantle-Cell (2) · Recurrence (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
90Y-octreotide, DOTA-Tyr(3)- (1) · Lenalidomide (1) · tafasitamab (1)
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Memorial Sloan Kettering Cancer Center (1)
Italy (1) · United States (1)
Anita Kumar, MD (1) · Maddalena Sansovini, MD (1)